Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has cytologically proven AML as defined by the World Health Organization (WHO) classification. The pretreatment AML karyotype should be documented.~* The leukemia is a de novo or secondary AML.~* The patient's blasts cells show expression of WT1 transcript, detected by quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR).The patient received the following therapy according to the Institution's standard of care.~  * For patients \< 60 years old: at least two induction chemotherapy treatments.~ * For patients \>= 60 years old: at least one induction chemotherapy treatment or alternative treatment.~* The first ASCI administration should be given within one year after the last chemotherapy administration. All screening procedures should be completed within seven weeks before the first ASCI administration.~* In the investigator's opinion and in compliance with the Institution Hematology Tumor Board's guidances, the patient should not be eligible for any additional chemotherapy treatment before the ASCI treatment.~* The clinical status of the patient at inclusion is one of the following:~  * Partial Remission (PR)~ * Morphologic complete remission with incomplete blood count recovery (CRi)~* Written informed consent has been obtained prior to the performance of any protocol-specific procedure.~* The patient is \>= 18 years of age at the time of signature of the first informed consent form.~* Eastern Cooperative Oncology Group performance status of 0, 1 or 2.~* Adequate hepatic and renal function defined as:~  * Serum bilirubin \< 1.5 times the Upper Limit of Nor-mal (ULN).~ * Serum ALT \< 2.5 times the ULN.~ * Calculated creatinine clearance \> 50 mL/min.~* In the view of the investigator, the patient can and will comply with the requirements of the protocol.~* If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, then she must practice adequate contraception for 30 days prior to treatment administration, have a negative pregnancy test and continue such precautions for 2 months after completion of the treatment administration series.~Exclusion Criteria:~* The patient was diagnosed with leukemic Central Nervous System (CNS) disease (e.g. before chemotherapy) or presents neurological symptoms at baseline suggestive of a CNS involvement.~* The patient has acute promyelocytic leukemia with t(15;17) (q22;q12), (PML/RARα) or variants.~* The patient has received, or is receiving, allogeneic Stem Cell Transplantation (SCT).~* The patient has received Fludarabine, Clofarabine or Cloretazine within 12 months preceding the ASCI treat-ment.~* The patient has hypercalcemia.~* The patient is known to be HIV-positive.~* The patient has symptomatic autoimmune disease such as, but not limited to multiple sclerosis, lupus, and in-flammatory bowel disease. Patients with vitiligo are not excluded.~* The patient has a history of allergic reactions likely to be exacerbated by any component of the study investigational product.~* The patient has other concurrent severe medical prob-lems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.~* The patient has another metastatic cancer disease.~* The patient has a history of congestive heart failure, coronary artery disease or previous myocardial infarction.~* The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the study procedures.~* The patient has received any investigational or non-registered medicinal product other than the study treat-ment within 30 days preceding the first dose of study treatment or plans to receive such a drug during the study period.~* The patient requires concomitant chronic treatment (more than 7 consecutive days) with systemic corticosteroids or any other immunosuppressive agents.~* The patient is receiving full dose subcutaneous heparins or is under anti-coagulation treatment.~* For female patients: the patient is pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Partial Remission Group (Type: EXPERIMENTAL): Adult patients in partial remission post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.
- Complete Remission Group (Type: EXPERIMENTAL): Adult patients in complete remission with incomplete blood count recovery post-induction chemotherapy, who received the GSK2130579A study product, administered sequentially, as follows: Cycle 1: 6 doses, each given at 2-week intervals; Cycle 2: 6 doses, each given at 3-week intervals; Cycle 3: 4 doses, each given at 6-week intervals; Cycle 4: 4 doses, each given at 3-month intervals, followed by 4 doses each given at 6-month intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).